Through the partnership, Moderna will have access to IBM’s quantum computers.
Additionally, Moderna and IBM scientists will use the MoLFormer AI model to help predict molecules’ properties and help understand potential mRNA medicines, according to an April 20 Moderna news release.
“IBM’s purpose is to be the catalyst to make the world work better, perfectly exemplified by this partnership with Moderna. We are witnessing a revolution in the world of computing, driven by extraordinary advances in AI and quantum computing,” Darío Gil, PhD, senior vice president and director of IBM Research said in the release. “Moderna will be able to take advantage of our multi-year research efforts in generative AI for therapeutics that can allow scientists to better understand how molecules behave and may facilitate creating entirely new ones.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
